NeOnc to Raise $15 Million After Reporting Glioma Trial Data

NeOnc Technologies agreed to sell 3.57 million shares, or pre-funded warrants in lieu of shares, along with warrants for another 3.57 million shares in a registered direct offering priced at $4.20 per share and warrant, expected to raise about $15 million before expenses. The warrants will be immediately exercisable at $4.20 per share and expire in five years, while the offering is expected to close around Sept. 10, 2026, subject to customary conditions. The financing follows topline Phase 2a data for NEO100 in recurrent or progressive IDH1-mutant glioma, including six-month progression-free survival of 48.9% and median overall survival of 26.09 months. However, the study was small and open-label, and the company still faces further clinical and regulatory work before any potential registration. NeOnc reported about $1.97 million in cash as of June 30, 2026, used roughly $11.8 million in operating cash during the first half of the year, and warned that its financing needs raise substantial doubt about its ability to continue as a going concern; the new issuance also represents material dilution for existing shareholders.